Abstract
Critical inspection of the world data of COVID-19 mortality rates per population number has been made and used to express extensive variations in mortality over the globe in terms of a powered parameter λ varying from 0 to 1.2 expressed as a measure of strength of primary infection, originating from China source. The copying process is degenerating successively while infection is passed on to secondary subjects. We have been able to correlate global data through this parameter; any value close to or less than 1 shows significant impact of diluted multiple secondary effect. Further, the scatter diagram shows no effect of temperature of the geographical location and so is likely as the virus is only being spread from either contact or close proximity – the virus does not need to face highs and lows of temperatures of the environment. It stays only in the range of human body temperature and appears to be stable in 36–40°C range. If it faces the environmental temperatures it is possible for its quicker deactivation but that situation never arises for this virus except when it spreads from surfaces.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
There is no requirement, the study is based only on globally available data
Clinical Protocols
Funding Statement
No funding agency and funding source is involved.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Global data resource centre https://coronavirus.jhu.edu/data
